Pain reduction with oral methotrexate in knee osteoarthritis
| ISRCTN | ISRCTN77854383 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN77854383 |
| EudraCT/CTIS number | 2013-001689-41 |
| Secondary identifying numbers | 15495 |
- Submission date
- 25/10/2013
- Registration date
- 25/10/2013
- Last edited
- 30/07/2024
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English Summary
Background and study aims
Osteoarthritis (OA) is the most common form of arthritis and is an increasingly common problem in our aging society. In the UK an estimated 8.5 million people are affected by OA, causing an enormous burden to health authorities, as well as considerable pain and disability to these individuals. A recent study by Arthritis Care reported that 81% of people with OA experience constant pain and 72% have important related conditions, such as high blood pressure or depression. Current treatments for knee OA are limited as they often only work for short periods and are not effective for all patients. As a result people with OA often live with severe pain and have significant difficulty in carrying out their normal day-to-day activities. There is therefore an urgent need to find new and better ways to manage pain for people with OA. Methotrexate has been used very successfully to treat inflammation in rheumatoid arthritis, and it is now the drug used most often to treat that type of arthritis. Recent studies suggest that inflammation is also important in OA, and that by reducing inflammation, pain will also be reduced. The aim of this study is to find out whether methotrexate is an effective treatment for reducing inflammation in knee OA and whether this leads to a reduction in pain.
Who can participate?
Patients aged 18 and over with knee OA
What does the study involve?
Participants are randomly allocated to take either methotrexate or a placebo (dummy drug), in combination with drugs licensed for use in pain management of OA. Knee pain and function, pain in other joints, quality of life, anxiety, depression, and health service resource use are measured at the start of the study, and after 3, 6, 9 and 12 months.
What are the possible benefits and risks of participating?
Not provided at time of registration
Where is the study run from?
1. Leeds Teaching Hospitals Trust (UK)
2. Aintree University Hospital NHS Trust (UK)
3. Staffordshire and Stoke-on-Trent Partnership NHS Trust (UK)
4. Northumbria Healthcare NHS Foundation Trust (UK)
5. NHS Fife (UK)
6. Cannock Chase Hospital (UK)
7. New Cross Hospital (UK)
8. Guy’s and St Thomas’s NHS Foundation Trust (UK)
9. King's College Hospital (UK)
10. Ashford & St Peter’s Hospitals NHS Foundation Trust (UK)
11. NIHR Wellcome Trust Southampton Clinical Research Facility (UK)
12. Harrogate and District NHS Foundation Trust (UK)
13. York Teaching Hospital NHS Foundation Trust (UK)
14. Salford Royal NHS Foundation Trust (UK)
15. Oxford University Hospitals NHS Foundation Trust (UK)
16. West Suffolk NHS Foundation Trust (UK)
When is the study starting and how long is it expected to run for?
January 2014 to January 2019
Who is funding the study?
Arthritis Research UK
Who is the main contact?
Sarah Kingsbury
S.R.Kingsbury@leeds.ac.uk
Contact information
Ms Sarah Kingsbury
Scientific
Scientific
LIRMM
Level 2 Chapel Allerton Hospital
Chapeltown Road
Leeds
LS7 4SA
United Kingdom
| Phone | +44 (0)113 392 4878 |
|---|---|
| S.R.Kingsbury@leeds.ac.uk |
Study information
| Study design | Randomised interventional treatment trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use contact details to request a participant information sheet |
| Scientific title | Pain Reduction with Oral Methotrexate in knee Osteoarthritis: a pragmatic phase III trial of Treatment Effectiveness |
| Study acronym | PROMOTE |
| Study hypothesis | Osteoarthritis (OA) is the most prevalent form of arthritis and is an increasingly common problem in our aging society. In the UK an estimated 8.5 million people are affected by OA, causing an enormous burden to health authorities, as well as considerable pain and disability to these individuals. A recent study by Arthritis Care reported that 81% of people with OA experience constant pain and 72% have important related conditions, such as hypertension or depression. Current treatments for knee OA are limited as they often only work for short periods and are not effective for all patients. As a result people with OA often live with severe pain and have significant difficulty in carrying out their normal day-to-day activities. There is therefore an urgent need to find new and better ways to manage pain for people with OA. Methotrexate has been used very successfully to treat inflammation in rheumatoid arthritis; it is now the commonest drug used to treat that type of arthritis. Recent studies suggest that inflammation is also important in OA, and that by reducing inflammation, pain will also be reduced. The trialists believe that methotrexate may be an effective treatment for reducing inflammation in knee OA and that this reduction in inflammation will lead to a reduction in pain. |
| Ethics approval(s) | First MREC approval date 23/09/2013; 13/YH/0279 |
| Condition | Topic: Primary Care Research Network for England; Subtopic: Not Assigned; Disease: All Diseases |
| Intervention | Patients will be randomised on a 1:1 basis to the intervention (Methotrexate, up to 25 mg per week) or placebo, used in combination with drugs licensed for use in pain management of OA Follow Up Length: 13 months |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase III |
| Drug / device / biological / vaccine name(s) | Methotrexate |
| Primary outcome measure | Average overall knee pain severity over the 1-week period prior to measurement; Timepoint(s): 6 months |
| Secondary outcome measures | Added 25/08/2016: Clinical endpoints: 1. Patient-reported knee pain 2. Disease activity and knee function 3. Pain in other joints 4. Number of withdrawals due to total knee replacement in the signal knee Measured at baseline, 3, 6, 9 and 12 months Quality of life endpoints: 1. Quality of life 2. Anxiety and depression Measured at baseline, 6 and 12 months Resource use endpoints: 1. Health service resource utilisation 2. Imaging/MRI endpoints (MRI sub study) 3. Synovitis and cartilage scores Measured at baseline, 6 and 12 months |
| Overall study start date | 01/01/2014 |
| Overall study end date | 08/01/2019 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | UK Sample Size: 160 |
| Total final enrolment | 155 |
| Participant inclusion criteria | Current inclusion criteria as of 25/08/2016: 1. Fulfil clinical American College of Rheumatology (ACR) Criteria for knee OA 2. Knee pain on most days in the last 3 months 3. Insufficient pain relief from, inability to tolerate, or contra-indication to oral and/or topical Non-steroidal anti-inflammatory drugs (NSAIDs) and/or opioids and/or Paracetamol. Moderate to severe pain of the signal knee as defined by a score of ≥40mm on a Visual analogue scale (VAS) (0-100mm) using the question “On average, how would you rate your knee pain during the last 3 months?” 4. Knee pain is the predominant pain condition 5. Patient able to identify a ‘signal’ painful knee (either the most painful knee or selected from equally painful knees) 6. A radiograph (X-Ray) of the signal knee within the last 2 years, with changes consistent with tibio-femoral OA 7. No change in the average weekly dose of oral/topical analgesics (including NSAIDs and Paracetamol) for at least 4 weeks 8. Has used chondroitin or glucosamine for at least 3 months with no change to the average weekly dose, is not using, or is willing to stop using if recently started 9. All male and female participants biologically capable of having children must agree to use a reliable method of contraception for the duration of the study and 24 weeks after the end of the study period. Acceptable methods of contraception are surgical sterilisation, oral, implantable or injectable hormonal methods, intrauterine devices or barrier contraceptives. If female and have potential for child bearing then a negative pregnancy test must be performed prior to starting treatment 10. The patient must be able to adhere to the study visit schedule and other protocol requirements 11. The patient must be capable of giving informed consent and the consent must be obtained prior to any screening procedures 12. All patients must have had a chest radiograph (X-Ray) within the last 6 months 13. Aged ≥ 18 years Previous inclusion criteria: 1. Fulfil clinical ACR Criteria for knee OA. 2. Knee pain on most days in the last 3 months. 3. Insufficient pain relief from, inability to tolerate, or contra-indication to oral and/or topical NSAIDs and/or opioids. Moderate to severe pain of the signal knee as defined by a score of ≥40mm on a VAS (0-100mm) using the question On average, how would you rate your knee pain during the last 3 months?. 4. Knee pain is the predominant pain condition. 5. Patient able to identify a signal painful knee (either the most painful knee or selected from equally painful knees). 6. A previous radiograph (X-Ray) of the signal knee with changes consistent with tibiofemoral OA. 7. No change in the average weekly dose of oral/topical analgesics (including NSAIDs) for at least 4 weeks. 8. Has used chondroitin or glucosamine for at least 3 months with no change to the average weekly dose, is not using or is willing to stop using if recently started. 9. Men and women must use adequate birth control measures (e.g. abstinence, oral contraceptives, Intra-uterine device, barrier method with spermicide, or surgical sterilisation) for the duration of the study and should continue such precautions for 6 months after receiving the last dose of MTX. If female and have potential for child bearing then a negative pregnancy test must be performed prior to starting treatment. 10. The patient must be able to adhere to the study visit schedule and other protocol requirements. 11. The patient must be capable of giving informed consent and the consent must be obtained prior to any screening procedures. 12. All patients must have had a chest radiograph (X-Ray) within the last 6 months. 13. Target Gender: Male & Female ; Lower Age Limit 18 years |
| Participant exclusion criteria | Current exclusion criteria as of 25/08/2016: 1. The presence of any inflammatory arthritis (e.g. gout, reactive arthritis, rheumatoid arthritis, psoriatic arthritis, seronegative spondylarthropathy, previous diagnosis of pseudogout in target joint with proven crystals on joint aspiration or elevated CRP at time of knee arthritis flare) or fibromyalgia. 2. Use of intra-articular (IA) hyaluronic acid in the signal knee within the 4 months preceding enrolment in the study. 3. Use of IA, IM or oral corticosteroids in the 3 months preceding enrolment. 4. Use of other anti-synovial agents (e.g. hydroxychloroquine or sulphasalazine) in the 2 months preceding the study. 5. Significant knee injury or any knee surgery within the 6 months preceding enrolment in the study. 6. A history of partial or complete joint replacement surgery in the signal knee at any time, listed for knee surgery, or anticipating knee surgery during the study period. 7. Commencement of physiotherapy or non-pharmacological knee OA treatment in the 2 months preceding the study. 8. The presence of non-OA causes of pain in the signal knee e.g. referred hip pain, osteonecrosis. 9. Women who are pregnant, breast-feeding, or men or women planning pregnancy within 18 months after screening (i.e. approximately 6 months following last study medications). 10. Use of any investigational (unlicensed) drug within 1 month prior to screening or within 5 half-lives of the investigational agent, whichever is longer. 11. Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral disease, or active current infection. 12. Uncontrolled disease states, such as moderate/severe asthma, Chronic Obstructive Pulmonary Disease (COPD) or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids, or recurrent infections. 13. Unwilling to keep alcohol intake to below the recommended maximum daily limit during the trial (2 units per day for women, 3 units per day for men). 14. Planned need for live vaccination during 12 months of study (e.g. for foreign travel) with exception of Zostavax® which is permissible. 15. Poor tolerability of venepuncture or lack of adequate venous access for required blood sampling during the study period. 16. Melanoma, squamous cell carcinoma or non-skin cancer in the past 3 years. 17. Intolerance to lactose. 18. Significant haematological or biochemical abnormality 18.1. Haemoglobin =<8.5 g/dL 18.2. WCC =<3.5 x 109/L 18.3. Neutrophils =<1.5 x 109/L 18.4. Platelets =<100 x 109/L 18.5. ALT >2 times ULN for the laboratory conducting the test. 18.6. Creatinine > 1.5 times ULN for the laboratory conducting the test 18.7. eGFR <30ml/minute Subjects with the following contra-indications to MRI scanning will not be included in the MRI substudy but may still be enrolled into the main study: 1. Pacemakers 2. Surgical clips within the head 3. Certain inner ear implants 4. Neuro-electrical stimulators 5. Metal fragments within the eye or head Previous exclusion criteria: 1. The presence of any inflammatory arthritis (e.g. gout, reactive arthritis, rheumatoid arthritis, psoriasis, psoriatic arthritis, seronegative spondylarthropathy) or fibromyalgia. 2. Use of intra-articular (IA) hyaluronic acid in the signal knee within the 4 months preceding enrolment in the study. 3. Use of IA, IM or oral corticosteroids in the 3 months preceding enrolment. 4. Use of other anti-synovial agents (e.g. hydroxychloroquine or sulphasalazine) in the 2 months preceding the study. 5. Significant knee injury or any knee surgery within the 6 months preceding enrolment in the study. 6. A history of partial or complete joint replacement surgery in the signal knee at any time, listed for knee surgery or anticipating knee surgery during the study period. 7. Commencement of physiotherapy or non-pharmacological knee OA treatment in the 2 months preceding the study. 8. The presence of non-OA causes of pain in the signal knee e.g. referred hip pain, osteonecrosis. 9. Women who are pregnant, breast-feeding, or men or women planning pregnancy within 18 months after screening (i.e. approximately 6 months following last study medications). 10. Use of any investigational (unlicensed) drug within 1 month prior to screening or within 5 half-lives of the investigational agent, whichever is longer. 11. Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease. 12. Uncontrolled disease states, such as moderate/severe asthma, COPD or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids, or recurrent infections. 13. Intake of alcohol above the recommended government guidelines (2 units per day for women, 3 units per day for men). 14. Planned need for live vaccination during 12 months of study (e.g. for foreign travel) or lack of immunity to chicken pox. 15. Poor tolerability of venepuncture or lack of adequate venous access for required blood sampling during the study period. 16. Melanoma or non-skin cancer in the past 3 years. 17. Intolerance to lactose. 18. Significant haematological or biochemical abnormality 18.1. Haemoglobin =<8.5 g/dL 18.2. WCC =<3.5 x 109/L 18.3. Neutrophils =<1.5 x 109/L 18.4. Platelets =<100 x 109/L 18.5. ALT >2 times ULN for the laboratory conducting the test. 18.6. Creatinine > 1.5 times ULN for the laboratory conducting the test 18.7. eGFR <30ml/minute Subjects with the following contra-indications to MRI scanning will not be included in the MRI substudy but may still be enrolled into the main study: 1. Pacemakers 2. Surgical clips within the head 3. Certain inner ear implants 4. Neuro-electrical stimulators 5. Metal fragments within the eye or head |
| Recruitment start date | 01/05/2014 |
| Recruitment end date | 31/08/2016 |
Locations
Countries of recruitment
- England
- Scotland
- United Kingdom
Study participating centres
Leeds Teaching Hospitals Trust
Chapel Allerton Hospital
Chapeltown Road
Leeds
LS7 4SA
United Kingdom
Chapeltown Road
Leeds
LS7 4SA
United Kingdom
Aintree University Hospital NHS Trust
Longmoor Lane
Liverpool
L9 7AL
United Kingdom
Liverpool
L9 7AL
United Kingdom
Staffordshire and Stoke-on-Trent Partnership NHS Trust
Haywood Hospital
High Lane
Burslem
Stoke-On-Trent
ST6 7AG
United Kingdom
High Lane
Burslem
Stoke-On-Trent
ST6 7AG
United Kingdom
Northumbria Healthcare NHS Foundation Trust
Rake Lane
North Shields
NE29 8NH
United Kingdom
North Shields
NE29 8NH
United Kingdom
NHS Fife
Victoria Hospital
Hayfield Road
Kirkcaldy
KY2 5AH
United Kingdom
Hayfield Road
Kirkcaldy
KY2 5AH
United Kingdom
Cannock Chase Hospital
Brunswick Road
Cannock
WS11 5XY
United Kingdom
Cannock
WS11 5XY
United Kingdom
New Cross Hospital
Wolverhampton Road
Wolverhampton
WV10 0QP
United Kingdom
Wolverhampton
WV10 0QP
United Kingdom
Guys and St Thomas’s
Guy's Hospital
Great Maze Pond
London
SE1 9RT
United Kingdom
Great Maze Pond
London
SE1 9RT
United Kingdom
King's College Hospital
King's College London
Suite 3, Golden Jubilee Wing
King’s College Hospital
Denmark Hill
London
SE5 9RS
United Kingdom
Suite 3, Golden Jubilee Wing
King’s College Hospital
Denmark Hill
London
SE5 9RS
United Kingdom
Ashford & St Peter’s Hospitals NHS Foundation Trust
Guildford Road
Chertsey
KT16 0PZ
United Kingdom
Chertsey
KT16 0PZ
United Kingdom
NIHR Wellcome Trust Southampton Clinical Research Facility
Southampton Centre for Biomedical Research
C Level West Wing
Mailpoint 218
Southampton General Hospital
Tremona Road
Southampton
SO16 6YD
United Kingdom
C Level West Wing
Mailpoint 218
Southampton General Hospital
Tremona Road
Southampton
SO16 6YD
United Kingdom
Harrogate and District NHS Foundation Trust
Lancaster Park Road
Harrogate
York
HG2 7SX
United Kingdom
Harrogate
York
HG2 7SX
United Kingdom
York Teaching Hospital NHS Foundation Trust
Wigginton Road
York
YO31 8HE
United Kingdom
York
YO31 8HE
United Kingdom
Salford Royal NHS Foundation Trust
Stott Lane
Salford
M6 8HD
United Kingdom
Salford
M6 8HD
United Kingdom
Oxford University Hospitals NHS Foundation Trust
Nuffield Orthopaedic Centre
Windmill Road
Headington
Oxford
OX3 7HE
United Kingdom
Windmill Road
Headington
Oxford
OX3 7HE
United Kingdom
West Suffolk NHS Foundation Trust
Hardwick Lane
Bury St Edmunds
IP33 2QZ
United Kingdom
Bury St Edmunds
IP33 2QZ
United Kingdom
Sponsor information
University of Leeds (UK)
University/education
University/education
Faculty Research Office
Room 10.110, Level 10 Worsley Building
Clarendon Way
Leeds
LS2 9NL
England
United Kingdom
| Website | http://www.leeds.ac.uk/ |
|---|---|
"ROR" |
https://ror.org/024mrxd33 |
Funders
Funder type
Charity
Arthritis Research UK (UK)
Private sector organisation / Other non-profit organizations
Private sector organisation / Other non-profit organizations
- Location
- United Kingdom
Results and Publications
| Intention to publish date | 31/12/2019 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | To be confirmed at a later date |
| IPD sharing plan | Fully anonymised datasets generated during the current study will be available upon request from Prof. Torgerson (e-mail, david.torgerson@york.ac.uk). |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol article | protocol | 04/03/2015 | Yes | No | |
| HRA research summary | 28/06/2023 | No | No | ||
| Results article | 30/07/2024 | 30/07/2024 | Yes | No |
Editorial Notes
30/07/2024: Publication reference added.
24/07/2019: IPD sharing statement added, contact details updated.
22/07/2019: The following changes were made to the trial record:
1. The overall trial end date was changed from 31/07/2018 to 08/01/2019.
2. The intention to publish date was changed from 31/07/2019 to 31/12/2019.
3. The total final enrolment number was added.
23/02/2018: Plain English summary added.
25/08/2016: The overall trial end date was changed from 30/06/2015 to 31/07/2018.
